Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 7/20 | 0.65 |
| ▸ | CA2 | P00918 | 7/20 | 0.65 |
| ▸ | CA9 | Q16790 | 7/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 6/20 | 0.33 |
| ▸ | CA5A | P35218 | 6/20 | 0.33 |
| ▸ | CA7 | P43166 | 6/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10061958 | 1.00 | CA1 (0.65) | CA1CA2CA9HPGDCYP2D6 | |
| SCHEMBL12425366 | 1.00 | CA1 (0.65) | CA1CA2CA9HPGDCYP2D6 | |
| SCHEMBL15959288 | 1.00 | CA1 (0.65) | CA1CA2CA9HPGDCYP2D6 | |
| SCHEMBL7155078 | 1.00 | CA1 (0.65) | CA1CA2CA9HPGDCYP2D6 | |
| SCHEMBL7080795 | 0.85 | CA2 (0.52) | CA1CA2CA9HPGDCYP1A2 | |
| SCHEMBL7148747 | 0.81 | CA2 (0.42) | CA1CA2CA9CYP2D6CYP1A2 | |
| SCHEMBL4179401 | 0.81 | CA2 (0.47) | CA1CA2CA9HPGDCA4 | |
| SCHEMBL5665101 | 0.81 | CA2 (0.81) | CA1CA2CA9CA4CA5A | |
| SCHEMBL5592102 | 0.81 | CA2 (0.81) | CA1CA2CA9CA4CA5A | |
| SCHEMBL2757717 | 0.81 | CA2 (0.81) | CA1CA2CA9CA4CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4380945-A2 | NOVEL SUGAR DERIVATIVES AND USES THEREOF TO PREPARE NOVEL SENOLYTIC AGENTS | Rubedo Life Sciences, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| US-20240182506-A1 | Sugar Derivatives and Uses Thereof to Prepare Novel Senolytic Agents | Rubedo Life Sciences, Inc. | 2024-06-06 | — | — | US | disclosed |
| WO-2023039292-A2 | NOVEL SUGAR DERIVATIVES AND USES THEREOF TO PREPARE NOVEL SENOLYTIC AGENTS | Rubedo Life Sciences, Inc. (US) | 2023-03-16 | — | — | WO | disclosed |
| WO-2023039293-A1 | COUMARIN DERIVATIVES OF SUGAR ANALOGS AND USES THEREOF | Rubedo Life Sciences, Inc. (US) | 2023-03-16 | — | — | WO | disclosed |
| US-20090048186-A1 | Monosaccharide Derivatives as Anti-Inflammatory and/or Anti-Cancer Agents | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-19 | — | — | US | disclosed |
| US-20080114031-A1 | MONOSACCHARIDE DERIVATIVES | RANBAXY LABORATORIES LIMITED (IN) | 2008-05-15 | — | — | US | disclosed |
| EP-1842855-A2 | MONOSACCHARIDE DERIVATIVES AS ANTI-INFLAMMATORY AND/OR ANTI-CANCER AGENTS | Ranbaxy Laboratories Limited (IN) | 2007-10-10 | — | — | EP | disclosed |
| US-6562514-B1 | Stabilized vanadium electrolyte solutions for all-vanadium redox cells and batteries | PINNACLE VRB LIMITED (AU) | 2003-05-13 | — | — | US | disclosed |
| US-6143443-A | ALL-VANADIUM REDOX BATTERY, COMPRISING THE STABILIZED ELECTROLYTE | PINNACLE ARB LIMITED (AU) | 2000-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048186-A1 | Monosaccharide Derivatives as Anti-Inflammatory and/or Anti-Cancer Agents | HLA-DRB1, MUC1, ASGR1 | CA1 2555/4885CA2 4209/4885CA9 1801/4885 |
| US-20240182506-A1 | Sugar Derivatives and Uses Thereof to Prepare Novel Senolytic Agents | GLA, SENP6, SENP8 | CA1 4265/4885CA2 4346/4885CA9 2553/4885 |
| US-20080114031-A1 | MONOSACCHARIDE DERIVATIVES | HLA-DRB1, MUC1, FUT5 | CA1 2839/4885CA2 4336/4885CA9 1937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.